Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has been invited to present the results from its phase 2a study of NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough at the 9th American Cough Conference in June 2023.
The American Cough Conference is the world's leading educational meeting for health care professionals involved in the research and management of patients with cough and is held every two years.
Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B), which prevents glutamate signalling. Ifenprodil represents a novel first-in-class treatment for both IPF and chronic cough.
"I am pleased that Algernon has accepted our invitation to present at the American Cough Conference," said Dr Peter Dicpinigaitis, professor of Medicine at Albert Einstein College of Medicine, editor-in-chief of LUNG, and conference chair.
READ: Algernon Pharmaceuticals reports further positive data from phase 2 study of Ifenprodil for IPF and chronic cough
"The NMDA receptor is a fascinating target, and Ifenprodil, if successful, would be a first-in-class treatment. I am excited about the drug's potential not only for cough in IPF, but also for the wider refractory chronic cough population," Dr Dicpinigaitis added.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets.
The company specifically investigates compounds that have never been approved in the US or Europe to avoid off-label prescription writing.
Contact the author at jon.hopkins@proactiveinvestors.com